*Refresh the page if the below document does not appear.
After the Himachal Pradesh Drug Regulatory Authority received information about some infamous activities, a pharmaceutical company in the state has come under scrutiny.
U.S. Department of Justice announced that Bayer AG had reached an agreement to pay $40 million to resolve claims that it used kickbacks and made false statements about three prescription drugs.
USFDA has authorised the use of Orkambi (lumacaftor/ivacaftor) in children with cystic fibrosis (CF) who are homozygous for the F508del mutation (F/F genotype) and are between the ages of 12 and 24 months.
Frontline nonsquamous non-small cell lung cancer patients treated with Merck’s Keytruda had a five-year survival rate of 19.4%, compared to a 5% five-year survival rate with chemotherapy in the past.
USFDA has granted IND approval to Aston Sci. Inc., a clinical stage biopharmaceutical company specialising in the clinical development of therapeutic cancer vaccines, for AST-301, its flagship product, for a phase 2 clinical trial.
Phase 3 data on the topical ED treatment MED3000 from Futura Medical have been released, paving the way for the company to request FDA approval of the treatment as an over-the-counter drug by the end of the month.
The establishment of a bulk drug park in
Jambusar has received preliminary approval
in Gujarat, and the state’s pharmaceutical
industry anticipates that the park will be
operational in three years.
If you don’t already have an account click the button below to create your account.Create New Account